CURETECH LTD.
🇧🇩Bangladesh
- Country
- 🇧🇩Bangladesh
- Ownership
- Subsidiary
- Established
- 2001-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://curetechbio.com
Clinical Trials
10
Active:3
Completed:5
Trial Phases
3 Phases
Phase 1:3
Phase 2:5
Not Applicable:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Phase 2
5 (50.0%)Phase 1
3 (30.0%)Not Applicable
2 (20.0%)Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2012-10-23
- Lead Sponsor
- CureTech Ltd
- Target Recruit Count
- 2
- Registration Number
- NCT00966251
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
- First Posted Date
- 2009-08-20
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- CureTech Ltd
- Target Recruit Count
- 13
- Registration Number
- NCT00962936
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
CT-011 MAb in DLBCL Patients Following ASCT
Phase 2
Completed
- Conditions
- Primary Mediastinal Large B-Cell LymphomaLymphoma, Large Cell, DiffuseLymphoma, Mixed Cell, Diffuse
- Interventions
- First Posted Date
- 2007-09-20
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- CureTech Ltd
- Target Recruit Count
- 72
- Registration Number
- NCT00532259
- Locations
- 🇺🇸
Moores UCSD Cancer Center, La Jolla,, California, United States
🇺🇸Scripps Cancer Center, San Diego, California, United States
🇺🇸Northside Hospital, Atlanta,, Georgia, United States
News
No news found